Ventilator associated pneumonia caused by extensive-drug resistant Acinetobacter species: Colistin is the remaining choice
Open Access
- 1 July 2016
- journal article
- research article
- Published by Taylor & Francis Ltd in Egyptian Journal of Anaesthesia
- Vol. 32 (3), 409-413
- https://doi.org/10.1016/j.egja.2016.03.004
Abstract
Introduction: Ventilator-associated pneumonia [VAP] is associated with increased morbidity and mortality especially when caused by extensive drug resistant [XDR] pathogens. Till now, little is known regarding the exact pathogenesis of XDR Acinetobacter baumannii [XDR-AB] infection. The aim of the present study was to identify prevalence and risk factors for VAP caused by XDR-AB in our intensive care unit, and to test the susceptibility pattern of tigecycline, carbapenems, and Colistin among the isolates. Methods: A prospective cohort study was conducted to enroll patients who developed VAP over 18-month period. All possible risk factors were documented as well as patient outcome. Susceptibility testing for the isolates was performed using inhibitory concentrations [MICs] determined by Epsilometer tests (E-tests) to Carbapenems, Tigecycline, and Colistin. Results: Among 544 consecutive patients admitted to our ICU during 18 months, Forty-seven patients developed VAP. The prevalence of XDR-AB was 63.8% (30 patients). No specific factor was associated with increase of the risk of acquisition of AB-VAP in our cohort either by univariate or by multivariate analysis. Carbapenems showed poor activity against all isolates [MIC range 10128 mg/L]. Tigecycline showed good activity against only 15 isolates [MIC range 0.25-2 mg/L]. Colistin demonstrated potent in vitro activity against all isolates of AB [MIC range 0.016-1 mg/L]. Conclusions: XDR AB-VAP is endemic in our ICU without a definite factor associated with increased risk of infection. Given that almost half of the strains are also resistant to tigecycline, colistin appears to be an appropriate first-line antimicrobial drug in critically ill patients developing VAP based on invitro results. (C) 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.Keywords
This publication has 29 references indexed in Scilit:
- Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: Clinical characteristics and outcomeIndian Journal of Critical Care Medicine, 2013
- Epidemiology and outcomes of ventilator-associated pneumonia in northern Brazil: an analytical descriptive prospective cohort studyBMC Infectious Diseases, 2013
- Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)Annals of Clinical Microbiology and Antimicrobials, 2013
- Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority TrialsClinical Infectious Diseases, 2012
- Renal and neurological side effects of colistin in critically ill patientsAnnals of Intensive Care, 2011
- Antimicrobial Resistance:Acinetobacter baumannii:Epidemiology, Antimicrobial Resistance, and Treatment OptionsClinical Infectious Diseases, 2008
- In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in ItalyAnnals of Clinical Microbiology and Antimicrobials, 2008
- In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophiliaJournal of Antimicrobial Chemotherapy, 2007
- Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unitDiagnostic Microbiology and Infectious Disease, 2005
- Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactamThe Lancet, 1994